C
Claudia Sommerer
Researcher at University Hospital Heidelberg
Publications - 180
Citations - 5619
Claudia Sommerer is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 36, co-authored 163 publications receiving 4604 citations. Previous affiliations of Claudia Sommerer include Charité & Heidelberg University.
Papers
More filters
Journal ArticleDOI
Everolimus in patients with autosomal dominant polycystic kidney disease.
Gerd Walz,Klemens Budde,Marwan Mannaa,Jens Nürnberger,Christoph Wanner,Claudia Sommerer,Ulrich Kunzendorf,Bernhard Banas,Walter H. Hörl,Nicholas Obermüller,Wolfgang Arns,Hermann Pavenstädt,Jens Gaedeke,Martin Büchert,Christoph May,Harald Gschaidmeier,Stefan Kramer,Kai-Uwe Eckardt +17 more
TL;DR: Within the 2-year study period, everolimus slowed the increase in total kidney volume of patients with ADPKD but did not slow the progression of renal impairment [corrected].
Journal ArticleDOI
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy : Second Consensus Report
Mercè Brunet,Teun van Gelder,Anders Åsberg,Vincent Haufroid,Vincent Haufroid,Dennis A. Hesselink,Loralie J. Langman,Florian Lemaitre,Pierre Marquet,Christoph Seger,Maria Shipkova,Alexander A. Vinks,Alexander A. Vinks,Pierre Wallemacq,Eberhard Wieland,Jean-Baptiste Woillard,Markus J. Barten,Klemens Budde,Helena Colom,Maja Theresa Dieterlen,Laure Elens,Kamisha L. Johnson-Davis,Paweł K. Kunicki,Iain MacPhee,Satohiro Masuda,Binu S. Mathew,Olga Millán,Tomoyuki Mizuno,Tomoyuki Mizuno,Dirk Jan A.R. Moes,Caroline Monchaud,Ofelia Noceti,Tomasz Pawinski,Nicolas Picard,Ron H.N. van Schaik,Claudia Sommerer,Nils Tore Vethe,Brenda C. M. de Winter,Uwe Christians,Stein Bergan +39 more
TL;DR: It is concluded that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade, and the Expert Committee concludes that Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacolimus therapy and to improve long-term outcomes for treated patients.
Journal ArticleDOI
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Klemens Budde,Thomas Becker,Wolfgang Arns,Claudia Sommerer,Petra Reinke,Ute Eisenberger,Stefan Kramer,W. Fischer,Harald Gschaidmeier,F Pietruck +9 more
TL;DR: Early elimination of calcineurin inhibitor by use of everolimus-based immunosuppression improved renal function at 12 months while maintaining efficacy and safety, indicating that this strategy may facilitate improved long-term outcomes in selected patients.
Journal ArticleDOI
Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial
Teun van Gelder,Helio Tedesco Silva,Johan W. de Fijter,Klemens Budde,Dirk Kuypers,Gunnar Tydén,Aleksander Lõhmus,Claudia Sommerer,Anders Hartmann,Yann Le Meur,Michael Oellerich,David W. Holt,Burkhard Tönshoff,Paul Keown,Scott B. Campbell,Richard D. Mamelok +15 more
TL;DR: The applied protocol of MMF dose adjustments based on target MPA exposure was not successful, partly because physicians seemed reluctant to implement substantial dose changes.
Journal ArticleDOI
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation
Julio Pascual,Stefan P Berger,Oliver Witzke,H. Tedesco,Shamkant Mulgaonkar,Y. Qazi,Steven J. Chadban,Federico Oppenheimer,Claudia Sommerer,Rainer Oberbauer,Yoshihiko Watarai,Christophe Legendre,Franco Citterio,Mitchell L. Henry,Titte R. Srinivas,Wen-Lin Luo,AnaMaria Marti,Peter Bernhardt,Flavio Vincenti +18 more
TL;DR: In kidney transplant recipients at mild-to-moderate immunologic risk, everolimus was noninferior to MPA for a binary composite end point assessing immunosuppressive efficacy and preservation of graft function.